In summary, these findings enhanced our understanding of the potential therapeutic implications of targeting PHGDH in FLT3-ITD+ AML and the underlying mechanism may be related to the regulation of Bcl-2/Bax pathway by PHGDH. The gene discussed is BCL2; the disease is acute myeloid leukemia.